



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	2	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)				
	B1	EP 436597 B1	04/02/1997	Protein Engineering Corporation		
	B2	GB 91/25579.4	02/12/1991	Cambridge Antibody Technology Ltd.		
	B3	GB 91/25582.8	02/12/1991	Cambridge Antibody Technology Ltd.		
	B4	WO 92-01047	01/23/1992	Cambridge Antibody Technology Ltd.		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
	C1	U.S. Appl. No. 08/484,893 Advisory Action dated November 3, 1997	
	C2	U.S. Appl. No. 08/484,893 Final office action dated March 28, 1997	
	C3	U.S. Appl. No. 08/484,893 Non-final office action dated July 20, 1999	
	C4	U.S. Appl. No. 08/484,893 Non-Final office action dated June 17, 1996	
	C5	U.S. Appl. No. 08/484,893 Non-final office action dated June 9, 1998	
	C6	U.S. Appl. No. 08/484,893 Notice of Allowance dated March 29, 2000	
	C7	U.S. Appl. No. 08/484,893 Restriction Requirement dated December 7, 1998	
	C8	U.S. Appl. No. 09/196,522 Examiner's Amendment dated January 28, 2004	
	C9	U.S. Appl. No. 09/196,522 Restriction Requirement dated November 27, 1999	
	C10	U.S. Appl. No. 09/196,522 Non-final office action dated April 20, 2000	
	C11	U.S. Appl. No. 09/196,522 Non-final office action dated January 3, 2001	
	C12	U.S. Appl. No. 09/196,522 Notice of Allowance dated May 3, 2004	
	C13	U.S. Appl. No. 09/196,586 Advisory Action dated December 5, 2008	
	C14	U.S. Appl. No. 09/196,586 Advisory Action dated May 4, 2007	
	C15	U.S. Appl. No. 09/196,586 Final office action dated September 22, 2006	
	C16	U.S. Appl. No. 09/196,586 Final office action dated April 17, 2001	
	C17	U.S. Appl. No. 09/196,586 Final office action dated December 22, 2004	
	C18	U.S. Appl. No. 09/196,586 Final office action dated September 15, 2008	
	C19	U.S. Appl. No. 09/196,586 Non final office action dated April 10, 2000	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	3	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

	C20	U.S. Appl. No. 09/196,586 Non-final office action dated April 4, 2002	
	C21	U.S. Appl. No. 09/196,586 Non-final office action dated December 28, 2005	
	C22	U.S. Appl. No. 09/196,586 Non-Final office action dated January 9, 2008	
	C23	U.S. Appl. No. 09/196,586 Non-final office action dated May 19, 2004	
	C24	U.S. Appl. No. 09/196,586 Restriction Requirement dated December 21, 1999	
	C25	U.S. Appl. No. 09/196,673 Advisory Action dated November 6, 2002	
	C26	U.S. Appl. No. 09/196,673 Advisory Action dated March 24, 2003	
	C27	U.S. Appl. No. 09/196,673 Final office action dated December 22, 2004	
	C28	U.S. Appl. No. 09/196,673 Final office action dated May 14, 2002	
	C29	U.S. Appl. No. 09/196,673 Non-final office action dated April 11, 2000	
	C30	U.S. Appl. No. 09/196,673 Non-final office action dated January 18, 2001	
	C31	U.S. Appl. No. 09/196,673 Non-final office action dated March 4, 2004	
	C32	U.S. Appl. No. 09/196,673 Notice of Allowance dated November 3, 2005	
	C33	U.S. Appl. No. 09/196,673 Restriction Requirement dated December 21, 1999	
	C34	U.S. Appl. No. 09/309,639 Non-final office action dated January 3, 2001	
	C35	U.S. Appl. No. 09/309,639 Official communication dated August 22, 2003	
	C36	U.S. Appl. No. 09/309,639 Restriction Requirement dated September 1, 2000	
	C37	U.S. Appl. No. 09/417,478 Advisory Action dated January 29, 2007	
	C38	U.S. Appl. No. 09/417,478 Final office action dated April 1, 2009	
	C39	U.S. Appl. No. 09/417,478 Final office action dated December 14, 2007	
	C40	U.S. Appl. No. 09/417,478 Final office action dated July 5, 2006	
	C41	U.S. Appl. No. 09/417,478 Non-final office action dated January 20, 2000	
	C42	U.S. Appl. No. 09/417,478 Non-final office action dated June 12, 2008	
	C43	U.S. Appl. No. 09/417,478 Non-final office action dated May 17, 2007	
	C44	U.S. Appl. No. 09/417,478 Non-final office action dated November 20, 2000	
	C45	U.S. Appl. No. 09/417,479 Non-final office action dated May 3, 2006	
	C46	U.S. Appl. No. 09/417,479 Restriction Requirement dated June 26, 2000	
	C47	U.S. Appl. No. 09/706,507 Non-final office action dated May 5, 2006	
	C48	U.S. Appl. No. 09/706,507 Restriction Requirement dated May 21, 2001	
	C49	U.S. Appl. No. 09/726,219 Non-final office action dated August 12, 2003	
	C50	U.S. Appl. No. 09/726,219 Notice of Allowance dated February 25, 2004	
	C51	U.S. Appl. No. 09/726,219 Restriction Requirement dated March 12, 2003	
	C52	U.S. Appl. No. 09/971,857 Advisory Action dated August 15, 1996	
	C53	U.S. Appl. No. 09/971,857 Examiner's Interview Summary Record dated December 13, 1996	
	C54	U.S. Appl. No. 09/971,857 Examiner's Interview summary Record dated April 24, 1997	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	4	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

	C55	U.S. Appl. No. 09/971,857 Final office action dated April 23, 1996	
	C56	U.S. Appl. No. 09/971,857 Non-final office action dated June 30, 1995	
	C57	U.S. Appl. No. 09/971,857 Notice of Allowance dated July 23, 1997	
	C58	U.S. Appl. No. 09/971,857 Response to 312 Amendment dated April 20, 1999	
	C59	U.S. Appl. No. 10/803,622 Examiner's Interview Summary dated March 20, 2008	
	C60	U.S. Appl. No. 10/803,622 Advisory Action dated July 31, 2007	
	C61	U.S. Appl. No. 10/803,622 Final office action dated April 10, 2007	
	C62	U.S. Appl. No. 10/803,622 Final office action dated February 17, 2009	
	C63	U.S. Appl. No. 10/803,622 Non-final office action dated July 3, 2008	
	C64	U.S. Appl. No. 10/803,622 Non-final office action dated July 5, 2006	
	C65	U.S. Appl. No. 10/803,622 Non-final office action dated October 2, 2007	
	C66	U.S. Appl. No. 10/803,622 Restriction Requirement dated April 10, 2006	
	C67	U.S. Appl. No. 10/803,653 Advisory Action dated October 11, 2007	
	C68	U.S. Appl. No. 10/803,653 Final office action dated May 8, 2007	
	C69	U.S. Appl. No. 10/803,653 Final office action dated November 5, 2008	
	C70	U.S. Appl. No. 10/803,653 Non-final office action dated January 18, 2008	
	C71	U.S. Appl. No. 10/803,653 Non-final office action dated October 4, 2006	
	C72	U.S. Appl. No. 10/803,653 Notice of Allowance dated May 21, 2009	
	C73	U.S. Appl. No. 11/555,464 Non-final office action dated March 5, 2009	
	C74	U.S. Appl. No. 11/555,519 Non-final office action dated March 5, 2009	
	C75	<b>Abbas, et al.</b> , "Cellular and Molecular Immunology," Saunders, Third Edition, p. 412 (1997)	
	C76	<b>Alberts, et al.</b> , "Molecular Biology of the Cell," Garland Publications, Third Edition, p. 96 (1994)	
	C77	<b>Avrameas and Ternynck</b> , "Natural Antibodies," in Delves, P., and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, pp. 1806-1809 (1998)	
	C78	<b>Barbas, et al.</b> , "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site," Proc. Natl. Acad. Sci. (USA), Vol. 88, pp. 7978-7982 (1991)	
	C79	<b>Barbas, et al.</b> , "Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen Specific Fabs," Methods: Companion Methods Enzymol., Vol. 2, pp. 119 (1991)	
	C80	<b>Beidler, et al.</b> , "Cloning and High Level Expression of a Chimeric Antibody with Specificity for Human Carcinoembryonic Antigen," J. Immunology, Vol. 141, pp. 4053-4060 (1988)	
	C81	<b>Berborowicz and Jaroszewski</b> , "Carcinoembryonic Antigen as an Autoantigen," Immunol. Ser., Vol. 52, pp. 65-83 (1982)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	5	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

	C82	<b>Berzofsky, et al.</b> , "Antigen-Antibody Interactions and Monoclonal Antibodies," in Paul, W., Fundamental Immunology, Second Edition, Chapter 12, pp. 332 (see also, Fourth Edition, 1994 (1999) Chapter 4, p. 91)	
	C83	<b>Beste, G., et al.</b> , "Small Antibody-like Proteins with Prescribed Ligand Specificities Derived from the Lipocalin Fold," Sci. USA, Vol. 96, No. 5, pp. 1898-19903, ISSN 0027-8424 (1999) Abstract	
	C84	<b>Boerner, et al.</b> , "Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human (Splenocytes)," J. Immunol. Vol. 147, pp. 86-95 (1991)	
	C85	<b>Breitling, et al.</b> , "A Surface Expression Vector for Antibody Screening," Gene, Vol. 104, pp. 147-153 (1991)	
	C86	<b>Buck</b> , Cell Biology, Vol. 3, pp. 179-188 (1992)	
	C87	<b>Burton, et al.</b> , "A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus from Combinatorial Libraries of Asymptomatic Seropositive Individuals," Proc. Natl. Acad. Sci., Vol. 88, pp. 10134-10137 (1991)	
	C88	<b>Casali and Notkins</b> , "Probing the Human [B-cell] Repertoire with EBV: Polyreactive Antibodies and CD5+ B Lymphocytes," Ann. Rev. Immunol., Vol. 7, pp. 513-535 (1989)	
	C89	<b>Chang, et al.</b> , "Expression of Antibody Fab Domains on Bacteriophage Surfaces: Potential Use of Antibody Selection," J. Immunol., Vol. 1047, pp. 3610-3614 (1991)	
	C90	<b>Cohen, P. L.</b> , "Systemic Autoimmunity," in Paul, W., Fundamental Immunology, Fourth Edition, Lippincott-Raven, p. 1608 (1997).	
	C91	<b>Delves, P.J.</b> , "Autoimmunity," in Delves, P. and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, p. 292 (1998)	
	C92	<b>Dighiero, et al.</b> , "Naturally Occurring Autoantibodies Against Nine Common Antigens in Human Sera," J. Immunol., Vol. 218, No. 128, pp. 2788-2792 (1982)	
	C93	<b>Fomsgaard, et al.</b> , "Auto-antibodies to Tumor Necrosis Factor in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections," Scand. J. Immunol., Vol. 30, pp. 219-223 (1989)	
	C94	<b>Geysen, H.M., et al.</b> , "A Priori Delineation of a Peptide Which Mimics a Discontinuous Antigenic Determinant," Molecular Immunology, Vol. 23, No. 7, pp. 709-715 (1986)	
	C95	<b>Golub, E.</b> , "The Limits of Medicine: How Science Shapes our Hope for the Cure," Times Books/Random House, p. 117-120 (1994)	
	C96	<b>Golub, E., and Green, D.</b> , "Immunology: A Synthesis," Sinauer Associates, Second Edition, p. 531 (1991)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	6	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

	C97	<b>Goodnow, et al.</b> , "Altered Immunoglobulin Expression and Functional Silencing of Self-Reactive B Lymphocytes in Transgenic Mice," Nature, Vol. 334, pp. 676-682 (1988)	
	C98	<b>Gram, et al.</b> , "In vitro Selection and Affinity Maturation of Antibodies from a Naïve Combinatorial Immunoglobulin Library," Proc. Natl. Acad. Sci USA, Vol. 89, pp. 3576-3580 (1992)	
	C99	<b>Griffiths, et al.</b> , "Human Anti-Self Antibodies with High Specificity from Phage Display Libraries, EMBO J., Vol. 12, pp. 725-734 (1993)	
	C100	<b>Griffiths, et al.</b> , "Isolation of High Affinity Human Antibodies Directly from Large Synthetic Repertoires," EMBO J., Vol. 13, pp. 3245-3260 (1994)	
	C101	<b>Guilbert, et al.</b> , "Naturally Occurring Antibodies Against Nine Common Antigens in Human Sera," J. Immunol., Vol. 128, pp. 2779-2787 (1982)	
	C102	<b>Hartley, O.</b> , "The Use of Phage Display in the Study of Receptors and Their Ligands," J. of Receptors and Signal Transduction, Vol. 22, Nos. 1-4, pp. 373-393 (2002)	
	C103	<b>Hartman and Wright</b> , "Identification of Autoantibodies Specific for the Neutrophil Adhesion Glycoproteins CD11b/CD18 in Patients with Autoimmune Disease (Neutroenia," Blood, Vol. 78, pp. 1096-1104 (1991)	
	C104	<b>Hirohata, et al.</b> , "Frequency Analysis of Human Peripheral Blood B Cells Producing IGM-Rheumatoid Factor," J. Immunol., Vol. 145, pp. 1681-1686 (1990)	
	C105	<b>Holness, et al.</b> , Journal of Cell Science, Vol. 107, pp. 2065-2070 (1994)	
	C106	<b>Hoogenboom, et al.</b> , "Building Antibodies from their Genes," Rev. Fr. Transfus. Hemobiol., Vol. 36, pp. 19-47 (1993)	
	C107	<b>Hoogenboom, et al.</b> , "Multi-Subunit Proteins on the Surface of Filamentous Phage: Methodologies for Displaying Antibody (Fab) Heavy and Light Chains," Nucl. Acids Res., Vol. 19, pp. 4133-4137 (1991)	
	C108	<b>Huse</b> , "Combinatorial Antibody Expression Libraries in Filamentous Phage," Chapter 5 of Antibody Engineer, Borrebaeck (ed.), W.H. Freeman and Co. N.Y. (1992)	
	C109	<b>International Search Report of European Patent Application No. 04005419.9</b> dated August 9, 2004	
	C110	<b>Jacobsson, K., et al.</b> , "Shot-gun Phage Display Mapping of Two Streptococcal Cell-Surface Proteins," Microbial Research, Vol. 152, No. 2, pp. 121-128, ISSN 0944-4013 (1997) Abstract	
	C111	<b>Kaushik, et al.</b> , "Comparative Analysis of Natural Antibody Specificities Among Hybridomas Originating from Spleen and Peritoneal Cavity of Adult NZB and BALB/c Mince," Scand. J. Immunol., Vol. 27, pp. 461-471 (1988)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	7	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

	C112	<b>Klein and Horejsi</b> , "Immunology" [Chapter 20, "immunological Tolerance"], Blackwell Scientific, Second Edition, p. 527 (1997)	
	C113	<b>Koga, et al.</b> , "Mouse-Human Chimeric Monoclonal Antibody to Carcinoembryonic Antigen (CEA): In Vitro and In Vivo Activities," Hybridoma, Vol. 9, pp. 43-56 (1990)	
	C114	<b>Landsteiner, K.</b> , "The Specificity of the Immune Response," quoted in Golub, E., Immunology: A Synthesis, Sinauer Associates, p. 19-25 [1991 book] (1987)	
	C115	<b>Lehninger, et al.</b> , Principles of Biochemistry, 2nd ed., Title Page, copy right page and p. G-4 only (1993)	
	C116	<b>Lobel, L.I., et al.</b> , "Filamentous Phage Displaying the Extracellular Domain of the hLH/CG Receptor Bind hCG Specifically," Endocrinology, Vol. 138, No. 3, pp. 1232-1239, ISSN: 0013-7227 (1997) Abstract	
	C117	<b>Logtenberg, et al.</b> , "Analysis of the Human Tonsil B Cell Repertoire by Somatic Hybridization: Occurrence of Both "Monospecific" and "Multispecific" (auto) Antibody-Secreting Cells," Eur. J. Immunol., Vol. 17, pp. 855-859 (1987)	
	C118	<b>Lydyard, et al.</b> , "The Antibody Repertoire of Early Human B Cells," Scand. J. Immunol., Vol. 31, pp. 33-43 (1990)	
	C119	<b>Mamula, et al.</b> , "The Specificity of Human Anti-Cytochrome c Autoantibodies that Arise in Autoimmune Disease," J. Immunol., Vol. 144, pp. 1835-1840 (1990)	
	C120	<b>Marks, et al.</b> , "Molecular Evolution of Proteins on Filamentous Phage," J. Biol. Chem., Vol. 267, p. 16007-16010 (1992)	
	C121	<b>McCafferty, J., et al.</b> , "Phage-Enzymes: Expression and Affinity Chromatography of Functional Alkaline Phosphatase on the Surface of Bacteriophage," Protein Engineering, Vol. 4, No. 8, pp. 955-961 (1991)	
	C122	<b>McHeyzer-Williams, et al.</b> , "Clonal Analysis of Autoantibody-Producing Cell Precursors in the Preimmune B Cell Repertoire," J. Immunol., Vol. 141, pp. 4118-4123 (1988)	
	C123	<b>Mullinax, et al.</b> , "Identification of Human Antibody Fragment Clones Specific For Tetanus Toxoid in a Bacteriophage $\lambda$ Immunoexpression Library," Proc. Natl. Acad. Sci., USA, Vol. 87, pp. 8095-8099 (1990)	
	C124	<b>Nemazee and Burk</b> , "Clonal Deletion of B Lymphocytes in a Transgenic Mouse Bearing Anti-MHC Class I Antibody Genes," Nature, Vol. 377, pp. 562-566 (1989)	
	C125	<b>Neumaier, et al.</b> , "Cloning of the Genes for T84.66, an Antibody that has a High Specificity and Affinity for Carcinoembryonic Antigen, and Expression of Chimeric Human/Mouse T84.66 Genes in Myeloma and Chinese Hamster Ovary Cells," Cancer Research, Vol. 50, pp. 2128-2134 (1990)	
	C126	<b>Nossal, G.V.J.</b> , "Cellular Mechanisms of Immune[ologic] Tolerance," Ann. Rev. Immunol., Vol. 1, pp. 33-62 (1983)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	8	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

	C127	<b>Nossal, G.V.J.</b> , "Molecular and Cellular Aspects of Immunologic Tolerance," Eur. J. Biochem., Vol. 202, pp. 729-737 (1991)	
	C128	<b>Persson, et al.</b> , "Generation of Diverse High-Affinity Human Monoclonal Antibodies by Repertoire Cloning," Proc. Natl. Acad. Sci., Vol. 88, pp. 2432-2436 (1991)	
	C129	<b>Portolano, S., et al.</b> , "A Human Fab Fragment Specific For Thyroid Peroxidase Generated By Cloning Thyroid Lymphocyte-Derived Immunoglobulin Genes in a Bacteriophage Lambda Library", Biochemical and Biophysical Research Communications, Vol. 179, No. 1, pp. 372-377 (1991)	
	C130	<b>Roitt, et al.</b> , Immunology, Second Edition, 1989, Ivan Roitt, et al., Gower Publishing, New York, p. 51 (1989)	
	C131	<b>Ruf., et al.</b> , "Various Expressions of a Unique Anti-Human Thymoglobulin Antibody Repertoire in Normal State and Autoimmune Disease," Blood, Vol. 78, pp. 1096-1104 (1991)	
	C132	<b>Smith, et al.</b> , "Phage Display," Chem. Rev., Vol. 97, pp. 391-410 (1997)	
	C133	<b>Svenson, et al.</b> , "IgG Autoantibodies Against Interleukin 1 $\alpha$ in Sera of Normal Individuals," Scand. J. Immunol., Vol. 29,, pp. 489-492 (1989)	
	C134	<b>Tomlinson, et al.</b> , "The Repertoire of Human Germline Vh Segments (Sequences Reveals about Fifty Groups of VH Segments] with Different Hypervariable Loops," J. Mol. Biol., Vol. 227, pp. 776-798 (1992)	
	C135	<b>Ura, et al.</b> , "Studies on Circulating Antibody Against Carcinoembryonic Antigen (CEA) and CEA-like Antigen in Cancer Patients," Cancer Letters, Vol. 25, pp. 283-295 (1985)	
	C136	<b>Waterhouse, et al.</b> , "Combinatorial Infection and in Vivo Recombination: A Strategy for Making Large Phage Antibody Repertoires," Nucl. Acids Res., Vol. 21, pp. 2265-2266 (1993)	
	C137	<b>Weidanz, J.A., et al.</b> , "Display of Functional Alphabets Single-Chain T-Cell Receptor Molecules on the Surface of Bacteriophage," J. Immunol. Methods, Vol. 221, (1-2), pp. 59-76, ISSN 0022-1759 (1998) Abstract	
	C138	<b>Wilson and Stanfield</b> , "Antibody-Antigen Interactions: New Structures and New Conformational Changes," Curr. Opin. Structural Biol., Vol. 4, pp. 857-867 (1994)	
	C139	<b>Winter, et al.</b> , "Making Antibodies by Phage Display Technology," Annu. Rev. Immunol., Vol. 12, pp. 433-455 (1994)	
	C140	<b>Promega Technical Bulletin, printed January 11, 2008, revised December 2006, pGEM-3ZF(+) Vector, 9 pages</b>	
	C141	<b>Promega Technical Bulletin, printed January 11, 2008, revised December 2006, pGEM-3ZF(-) Vector, 9 pages</b>	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	9	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

	C142	<b>Stratagene Instruction Manual, printed January 11,m 2008, revised 2003, pBluescript II Phagemic Vectors, 37 pages</b>	
	C143	First Amended Complaint, Filed March 8, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (24 pages) (U.S. District Court, District of Columbia)(signed by John S. Skilton, Attorney for Plaintiff.)	
	C144	Cambridge Antibody Technology Limited's Answer to First Amended Complaint, Filed March 22, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia)(signed by Brian H. Corcoran, Attorney for Defendant).	
	C145	<b>Il'ichev, A.A., et al.</b> , "M13 Filamentous Bacteriophage in Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990).	
	C146	<b>Iliychev, A.A., et al.</b> , "M13 Filamentous Bactiophage for Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990). (In Russian with Translated Abstract)	
	C147	Redacted Agreement Between Medical Research Council and Cambridge Antibody Technology Limited and Cambridge Antibody Technology Group plc, made 01 January 1997	
	C148	Deposition Transcript of David W. Clough, taken April 19, 2002 (Morphosys AG v. Cambridge Antibody Technology Limited, U.S. District Court, Northern District of Illinois, Eastern Division).	
	C149	E.I. du Pont de Nemours v. Cetus Corp., 19 USPQ2d 1174, (DC N.Cal. 1990).	
	C150	OddzOn Products Inc. v. Just Toys Inc., 43 USPQ2d 1641(CAFC 1997).	
	C151	Deposition Transcript of George P. Smith, Ph.D., taken 14 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C152	Deposition Transcript of Dr. David Chiswell, taken 29 April 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C153	Deposition Transcript of Dr. Gregory Paul Winter, taken April 30, 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C154	Vol. I - Deposition Transcript of Sean Malcolm Walton, taken 01 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C155	Vol. II - Deposition Transcript of Sean Malcolm Walton, taken 02 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C156	Chiswell memo, dated 30 July 1990, transmitting a copy of the Collaborative Agreement between Cambridge Antibody Technology and The Medical Research Council, dated July 27, 1995.	
	C157	Declaration of George P. Smith, Ph.D., Under 37 C.F.R. § 1.132, executed 30 June 1995 (submitted during the prosecution of U.S. Application No. 08/322,352).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	10	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

	C158	Declaration of Brian K. Kay, Ph.D., executed 28 June 1998, (submitted during the prosecution of European Appln. No. 91913039.3)	
	C159	Abstract of George P. Smith, Grant No. 1R01GM41478-01A1, Project Start Date: July 1, 1989, Dept. of Health & Human Services.	
	C160	Smith Grant Application, entitled: "Filamentous Phage Physiology", dated November 1, 1988	
	C161	Administration Agreement between Cambridge Antibody Technology Ltd. and Medical Research Council, dated 01 August 1991 (Redacted).	
	C162	Fax from John McCafferty (of Cambridge Antibody Technology Limited) to Sean Walton (of Mewburn Ellis) regarding the Smith grant application.	
	C163	E-mail message from John McCafferty (of Cambridge Antibody Technology Limited) to Brian Kay regarding the Smith grant application	
	C164	Letter to Craig Panner (of the Academic Press) from John McCafferty (Cambridge Antibody Technology Limited) regarding the Smith grant application	
	C165	Fax to John McCafferty, Ph.D. (of Cambridge Antibody Technology Limited) from Craig Panner (of Academic Press) dated June 10, 1996.	
	C166	Smith, G. P., "1988 - A Year of Discovery", <i>Phage Display of Peptides and Proteins</i> , Academic Press, Inc. (1996), pp. xvii-xix.	
	C167	<u>Northern Telecom Inc. v. Datapoint Corp.</u> , 15 USPQ 1321., (CAFC 1990). Letter of Dr. Smith Re: NIH grant proposals, Dated June 27, 1997	
	C168	Barbas and Lerner "Combinatorial Immunoglobulin Libraries on the surface of phage (Phabs): rapid selection of anti-specific fabs." <i>Methods: a companion to methods in Enzymology Vol. 2 (2): 119-124 (1991).</i>	
	C169	Document D91 in Appeal No. T0639/02-334: Better et al. (1988). <i>Science</i> 240, 1041-1043	
	C170	Document D92 in Appeal No. T0639/02-334: Sambrook & Russell (2001). <i>Molecular cloning: a laboratory manual 3rd Edition</i> , Cold Spring Harbor Press; particular pages 18.115 to 18.122 "Filamentous phage display"	
	C171	Document D17: Vieira and Messing (1987), <i>Methods Enzymol.</i> 153, 3-11	
	C172	Document D8: Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodology for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Research</i> , Vol 19, No. 15 (1991), pages 4133-4137.	
	C173	Opposition to European patent EP-B-0589877, cited opposition document D9: De La Cruz et al. "Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage", <i>J. Bio. Chem.</i> 263: 4318-4322 (1988)	
	C174	Opposition to European patent EP-B-0589877, cited opposition document D23: US 517 659 "Affymax priority document", entitled "Recombinant Library Screening Methods", priority document filed 1 May 1990 for EP-A-0 527 839 (Article 54(3) EPC)	
	C175	Complaint filed 4/23/99	
	C176	First Amended Complaint filed 5/6/99	
	C177	Defendant Cambridge Antibody Technology, Limited's Motion to Dismiss plaintiff MorPhosys Ag's Complaint filed 06/8/99	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/416,902
				<b>Filing Date</b>	October 13, 1999
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
<b>Sheet</b>	11	of	11	<b>Attorney Docket Number</b>	05569.0004.DVUS06

	C178	Response of Plaintiff MorphoSys Ag to Cambridge Antibody Technology Ltd's First Set of Interrogatories and Request for Production of Documents and Things filed 10/18/99	
	C179	Plaintiff's Supplemental Answer to Interrogatory No. 2	
	C180	Response of Plaintiff-MorphoSys AG to Cambridge Antibody Technology Ltd.'s First Set of Interrogatories and Request for Production of Documents and Things filed 3/27/00	
	C181	Response of Plaintiff MorphoSys AG to Cambridge Antibody Technology Ltd.'s Second set of Interrogatories filed 7/3/002	
	C182	Response of MorphoSys AG to Cambridge Antibody Technology's Third Set of Interrogatories filed 8/14/007	
	C183	Declaration of Edward S. Golub, Ph.D. in Support of Morpho Sys Motion for Partial Summary Judgment of Noninfringement filed 9/1/00	
	C184	Edward S. Golub, Ph.D. Curriculum Vitae	
	C185	Expert Report of Edward S. Golub, Ph.D. dated 6/00 (with Exhibit 1) E. S. Golub Curriculum Vitae-Exhibit 2 E.S. Golub Validity Report and Exhibit 3 Declaration of E.S. Golub regarding Immunological Concepts	
	C186	Rebuttal Expert Report of Edward S. Golub, Ph.D.	
	C187	Reply of Edward S. Golub, Ph.D. to Rebuttal Expert Reports of Edward P. Cohen, M.D. and Ronald II, Jackson, Ph.D. dated 08/01/00	
	C188	Declaration of Carlos F. Barbas III, Ph.D. in Support of MorphoSys Motion for Partial Summary Judgment of Noninfringement filed 9/1/00	
	C189	Carlos F. Barbas III, Ph.D. Curriculum Vitae	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.